HC Wainwright & Co. Initiates Coverage On Neumora Therapeutics with Buy Rating, Announces Price Target of $30
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has initiated coverage on Neumora Therapeutics with a Buy rating and set a price target of $30.
October 01, 2024 | 10:26 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has initiated coverage on Neumora Therapeutics with a Buy rating and a price target of $30, indicating a positive outlook.
The initiation of coverage with a Buy rating and a specific price target of $30 by HC Wainwright & Co. suggests a positive sentiment towards Neumora Therapeutics. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100